PepGen, Inc. (NASDAQ:PEPG) Given Consensus Rating of “Moderate Buy” by Analysts

PepGen, Inc. (NASDAQ:PEPG) has been given an average rating of “Moderate Buy” by the six analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $11.80.

PEPG has been the topic of a number of analyst reports. Guggenheim increased their price objective on PepGen from $6.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Oppenheimer initiated coverage on PepGen in a report on Wednesday, February 25th. They set an “outperform” rating and a $15.00 price objective on the stock. Wedbush lowered their price objective on PepGen from $9.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a report on Tuesday, April 21st.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Rangeley Capital LLC increased its holdings in shares of PepGen by 133.3% during the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after acquiring an additional 20,000 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of PepGen during the 2nd quarter valued at about $44,000. Heights Capital Management Inc. acquired a new position in shares of PepGen during the 3rd quarter valued at about $46,000. Burkehill Global Management LP acquired a new position in shares of PepGen during the 3rd quarter valued at about $46,000. Finally, Militia Capital Partners LP bought a new stake in PepGen during the 3rd quarter valued at approximately $72,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Price Performance

PEPG opened at $1.79 on Friday. PepGen has a fifty-two week low of $1.01 and a fifty-two week high of $7.80. The business has a 50-day moving average of $3.52 and a 200-day moving average of $4.82. The company has a market capitalization of $123.81 million, a PE ratio of -0.74 and a beta of 2.01.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.13. On average, equities research analysts expect that PepGen will post -1.22 earnings per share for the current fiscal year.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).